Publications

Leading Innovation Through Research and Discovery
Translating cutting-edge collagen science into transformative regenerative medicine.
History

10+ Years of Research

Built on over a decade of R&D into collagen’s biological activity, Conexeu’s proprietary formulations are being developed to potentially support faster and more complete tissue repair.
Our collagen-based scaffold platform is under investigation for multiple high-value therapeutic and aesthetic applications, representing a potential leap forward in regenerative medicine.

Patents

COLLAGEN IP
  • Secured in the USA, Japan, EU, Australia, and pending in Canada.
  • Conexeu’s patented extracellular matrix (ECM) technology — a collagen-derived, biomimetic platform — is being developed as a potential advance in regenerative medicine and tissue engineering, supported by over a decade of research at the University of British Columbia.

Investors

A Transformational Opportunity in Regenerative Medicine

Growing Market Demand.

The global shift toward safer, natural aesthetic and reconstructive solutions continues to expand.

Provisional Science.

Supported by preclinical, peer-reviewed data, Conexeu’s patented collagen approach is being investigated for applications ranging from facial rejuvenation to large-volume body contouring.

Seasoned Leadership.

World-renowned aesthetic surgeon, tissue-engineering PhDs, former CEOs/CMOs of global aesthetics leaders & medical device veterans with proven FDA-clearance track records.

Learn More

“Join Us in Shaping the Future of Regenerative Medicine”

At Conexeu, we’re not just introducing another facial filler; we’re igniting a paradigm shift in how medicine approaches tissue restoration. From investors seeking high-growth opportunities to clinicians pursuing safer and more effective therapies—everyone benefits from a future driven by true regeneration.
Join our newsletter to track our innovations and breakthroughs.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.